Advancing Evidence in Cabotegravir for HIV Prevention (General)

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV prevention across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.

ViiV ISR Area Of Interest Overview

Drug/Product Alignment

ViiV Products in Scope:	Cabotegravir
Treatment Type:	Long Acting - PreP
Specify the Treatment Type:

Area of Interest/DataGap Description

Core Focus Area:	Open
Example Research Question(s):	All scientifically sound and relevant research questions related to this area will be considered.

Desirable Study Parameters

Populations of Interest:	All Patient Types
Geographical Regions:	Global

Version 20250909-disp

- Back to Top -

Advancing Evidence in Cabotegravir for HIV Prevention (General)

ViiV ISR Area Of Interest Overview

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study